MarketScreener Homepage > Equities > Tokyo Stock Exchange > Otsuka Corporation 4768 JP3188200004

Report

End-of-day quote Tokyo Stock Exchange - 01/25
5300	JPY		+2.51%

01/12

PRESS RELEASE : Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

2020

OTSUKA CORPORATION : Ex-dividend day for final dividend

2020

Dual-Listed Aurinia In Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co. for Development and Commercialization of Voclosporin in Europe and Japan

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Tokyo Stock Exchange

01/21/2021	01/22/2021	01/25/2021	01/26/2021	01/27/2021	Date
5100	5170	5300	5400	5520	Last
383600	396100	515300	454700	721300	Volume
+2.10%	+1.37%	+2.51%	+1.89%	+2.22%	Change

Financials

Sales 2020	830 B 7 970 M 7 970 M
Net income 2020	40 294 M 387 M 387 M
Net cash position 2020	183 B 1 761 M 1 761 M
P/E ratio 2020	25,9x
Yield 2020	2,11%

Sales 2021	868 B 8 339 M 8 339 M
Net income 2021	44 630 M 429 M 429 M
Net cash position 2021	203 B 1 947 M 1 947 M
P/E ratio 2021	23,5x
Yield 2021	2,24%

Capitalization	1 047 B 10 057 M 10 053 M
EV / Sales 2020	1,04x
EV / Sales 2021	0,97x
Nbr of Employees	8 912
Free-Float	57,5%

More Financials

Company

Otsuka Corporation specializes in IT services for businesses and public institutions. Net sales break down by activity as follows: - development and integration of software and systems (61%): integrated management software packages, planning and design software, business process management solutions, information platforms, document management software, voice and data transmission solutions, etc. The group also...

Sector

IT Services & Consulting

Calendar

02/04

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Otsuka Corporation

Trading Rating :

Investor Rating :

More Ratings

All news about OTSUKA CORPORATION

01/12	PRESS RELEASE : Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0..	DJ
2020	OTSUKA CORPORATION : Ex-dividend day for final dividend	FA
2020	Dual-Listed Aurinia In Collaboration and Licensing Agreement with Otsuka Phar..	MT
2020	Aurinia Pharmaceuticals to Collaborate With Otsuka Pharmaceutical for Develop..	MT
2020	OTSUKA : Reports Results of Two Global Clinical Trials for Uncontrolled Hyperten..	MT
2020	OTSUKA CORPORATION : quaterly earnings release
2020	Japan looks to AI as coronavirus challenges go-and-see quality control mantra	RE
2020	OTSUKA CORPORATION : half-yearly earnings release
2020	Mylan gets Indian regulatory approval for tuberculosis drug	RE
2020	Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries	RE
2020	OTSUKA CORPORATION : annual earnings release
2019	OTSUKA CORPORATION : Ex-dividend day for final dividend	FA
2019	FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%	RE
2019	Musashi Seimitsu to co-develop new engine with Israel's Aquarius	RE
2019	OTSUKA CORPORATION : Half-year results	CO

More news

News in other languages on OTSUKA CORPORATION

2020	BOURSES ASIATIQUES : Tokyo rassurée, Hong Kong préoccupée
2020	Tokyo clôture en hausse, le moral des entreprises japonaises s'améliore
2020	OTSUKA CORPORATION : publication des résultats trimestriels
2020	OTSUKA CORPORATION : Veröffentlichung des Quartalsergebnisses
2020	Tokyo finit en retrait, plombée par SoftBank Group

More news

Analyst Recommendations on OTSUKA CORPORATION

2013

Europe backs new dual-action Novartis lung drug

More recommendations

Provided by Scoopnest.com

Chart OTSUKA CORPORATION

Duration : Period :

Otsuka Corporation Technical Analysis Chart | 4768 | JP3188200004 | MarketScreener

Full-screen chart

Technical analysis trends OTSUKA CORPORATION

	Short Term	Mid-Term	Long Term
Trends	Neutral	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	12
Average target price	5 580,83 JPY
Last Close Price	5 520,00 JPY
Spread / Highest target	8,70%
Spread / Average Target	1,10%
Spread / Lowest Target	-13,9%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Yuji Otsuka	President, Representative Director & GM-Marketing
Minoru Sakurai	Director & General Manager-Technology
Kazuyuki Katakura	Director, GM-Sales & Deputy GM-Marketing
Toshiyasu Takahashi	Director & Senior Lead Managing Executive Officer
Katsuhiro Yano	Director & Managing Executive Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

OTSUKA CORPORATION	-2.75%	9 876



VERISK ANALYTICS	-9.20%	30 648
SAMSUNG SDS CO.,LTD.	16.25%	14 198
CHANGE HEALTHCARE INC.	28.74%	7 338
REPLY S.P.A.	8.81%	4 718
CHINA TRANSINFO TECHNOLOGY CO., LTD	-3.29%	4 529

More Results